RVTY logo

Revvity, Inc. Stock Price

NYSE:RVTY Community·US$11.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 11 Fair Values set on narratives written by author

RVTY Share Price Performance

US$105.57
-9.50 (-8.26%)
US$113.67
Fair Value
US$105.57
-9.50 (-8.26%)
7.1% undervalued intrinsic discount
US$113.67
Fair Value
Price US$105.57
AnalystConsensusTarget US$113.67
AnalystLowTarget US$100.00
AnalystHighTarget US$162.00

RVTY Community Narratives

AnalystConsensusTarget·
Fair Value US$113.67 7.1% undervalued intrinsic discount

RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AnalystLowTarget·
Fair Value US$100 5.6% overvalued intrinsic discount

Regulatory Shifts Will Pressure Diagnostics Yet Spur Measured Turnaround

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value US$146.63 28.0% undervalued intrinsic discount

Genomics And Automation Will Expand Diagnostics In Aging Populations

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$113.67
7.1% undervalued intrinsic discount
Revenue growth
5.09% p.a.
Profit Margin
20.27%
Future PE
20.81x
Share price in 2028
US$144.73
US$100
5.6% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
4.84% p.a.
Profit Margin
12.75%
Future PE
30.52x
Share price in 2028
US$124.67
US$146.63
28.0% undervalued intrinsic discount
Revenue growth
6.02% p.a.
Profit Margin
21.21%
Future PE
26.03x
Share price in 2028
US$182.82

Updated Narratives

RVTY logo

RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead

Fair Value: US$113.67 7.1% undervalued intrinsic discount
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RVTY logo

Regulatory Shifts Will Pressure Diagnostics Yet Spur Measured Turnaround

Fair Value: US$100 5.6% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RVTY logo

Genomics And Automation Will Expand Diagnostics In Aging Populations

Fair Value: US$146.63 28.0% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Adequate balance sheet with moderate growth potential.

1 Risk
2 Rewards

Revvity, Inc. Key Details

US$2.8b

Revenue

US$1.3b

Cost of Revenue

US$1.6b

Gross Profit

US$1.3b

Other Expenses

US$232.5m

Earnings

Last Reported Earnings
Sep 28, 2025
Next Reporting Earnings
n/a
2.05
55.25%
8.26%
43.6%
View Full Analysis

About RVTY

Founded
1937
Employees
11000
CEO
Prahlad Singh
WebsiteView website
www.revvity.com

Revvity, Inc. provides health sciences solutions, technologies, and services. The company provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and DNA sequencing services; and instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, screening newborns for rare genetic conditions, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific, BioQule, BoBs, chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPatternTM, Evolution Evoya, explorer, Fontus, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Omni Bead Ruptor, Omni Bead Ruptor Elite, Omni Tip, Pannoramic, Panthera Puncher, PG-Seq, PG-Find, PreNAT II, Prime, Protein Clear, ProteinEXact, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord, VICTOR2D, and Zephyr names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Recent RVTY News & Updates

Recent updates

No updates